Proliferative Lupus Nephritis Treatment With Chloroquine and Hydroxychloroquine
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03687905|
Recruitment Status : Recruiting
First Posted : September 27, 2018
Last Update Posted : September 27, 2018
|Condition or disease||Intervention/treatment|
|Proliferative Nephritis Chloroquine Retinopathy||Drug: Chloroquine Drug: Hydroxychloroquine|
All patients will fulfill the diagnostic criteria of SLE. The diagnosis of systemic lupus erythematosus is based on clinical and laboratory criteria. The criteria set developed by the American College of Rheumatology (ACR) and diagnosed wih lupus nephritis class III and IV .
- Children and adolescents who fulfill diagnostics criteria of SLE and diagnosed with lupus nephritis class III and IV.
- All patients will be received steroids , MMF and Angiotensin Converting Enzyme.
- Patients diagnosed with lupus nephritis class I,II,V and VI.
- Patients received Cyclophosphamide in stead of MMF.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||60 participants|
|Target Follow-Up Duration:||6 Months|
|Official Title:||Comparative Study Between Chloroquine and Hydroxychloroquine as Therapeutic Modalities for Children and Adolescents With Proliferative Lupus Nephritis|
|Actual Study Start Date :||September 18, 2018|
|Estimated Primary Completion Date :||March 31, 2019|
|Estimated Study Completion Date :||September 30, 2019|
Lupus nephritis III or IV/chloroquine
receiving chloroquine with daily dose 5 mg/kg
group1 received chloroquine .
Other Name: alexoquine
Lupus nephritis III or IV/hydroxychloroquine
receiving hydroxycholorquine with daily dose 5 mg/kg
Group 2 received hydroxychloroquine
Other Name: hydroquine
Systemic lupus erythematosus
not received hydroxychloroquine nor chloroquine .
- Fundus examination as screening test [ Time Frame: 12 months ]Detection of chloroquine and hydroxychloroquine related retinal toxicity at early stage.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03687905
|Contact: Fatma S Gheet, M.B.,BChfirstname.lastname@example.org|
|Contact: Fatma S Gheet, M.B.,BCh +201148157993 email@example.com|
|Principal Investigator:||Fatma S Gheet, M.B.,BCh||Tanta University|